Compass Therapeutics Corp - CMPX Company Short-Term Debt

This daily price chart for Compass Therapeutics (CMPX) shows the current level at 0.00. Compass Therapeutics develops complex bispecific antibodies that target two immune markers, effectively blocking tumor escape pathways. The business relies on patent-protected molecules to ensure long-term, high-yield monetization. Risks associated with a limited portfolio are mitigated by a pipeline of promising candidates that have demonstrated excellent results in primary trials.

Short-term debt measures the total liabilities with a maturity of up to one year, determining current liquidity and the risk of cash flow gaps. A decrease in this metric signals financial stability, whereas an increase necessitates an analysis of refinancing sources. By analyzing the short-term debt trend on GURU.Markets, an investor assesses the operational flexibility of the business. For Compass Therapeutics (CMPX), this is critical when financing the development of immunotherapeutic antibodies. A valuable IP portfolio allows the company to raise capital on favorable terms.